Sep 16, 2026 · 20 min · 12 segments
Our guest this week is Antoine Pivron, Vice President of Withings Health Solutions, where he leads the global B2B healthcare division across Europe and the US, working with more than 300 healthcare…
Antoine PivronGuestGlennHostHello and welcome to the Healthcare Daily Podcast.
Our guest this week is Anton Pivois, Vice President of Wyvins Health Solutions, where he leads the global B2B healthcare division across Europe and the US, working with more than 300 healthcare partners and supporting more than 1 million patients in remote monitoring programs.
Today, we're talking about GLP-1 therapies, the weight loss drugs that have captured global attention.
But beyond the headlines about shedding pounds, there's a bigger conversation unfolding about how we monitor, engage and support patients over the long term.
Antoine's organisation is working in partnership with Novo Nordisk and has also partnered with Juniper in the UK, bringing together pharmaceutical expertise and hardware technology.
In this episode, we'll explore how remote patient monitoring, body composition data and new models of care are shaping the next phase of GLP-1 therapy and what this means for patients, clinicians and healthcare systems.
Read the full transcript.
Create an account to read the whole episode, search across every transcript, and follow the shows you care about.
Hello and welcome to the Healthcare Daily Podcast.
Our guest this week is Anton Pivois, Vice President of Wyvins Health Solutions, where he leads the global B2B healthcare division across Europe and the US, working with more than 300 healthcare partners and supporting more than 1 million patients in remote monitoring programs.
Today, we're talking about GLP-1 therapies, the weight loss drugs that have captured global attention.
But beyond the headlines about shedding pounds, there's a bigger conversation unfolding about how we monitor, engage and support patients over the long term.
Antoine's organisation is working in partnership with Novo Nordisk and has also partnered with Juniper in the UK, bringing together pharmaceutical expertise and hardware technology.
In this episode, we'll explore how remote patient monitoring, body composition data and new models of care are shaping the next phase of GLP-1 therapy and what this means for patients, clinicians and healthcare systems.
